Astromech Buys Form Bio to Combine Evolutionary AI and Genomic Design

Unite.AI
Read full story· 4 min
Astromech acquired Form Bio for $230M to integrate its evolutionary AI with Form Bio's genetic medicine design tools, aiming to enhance gene therapy vector design and genomic quality assessment. The merger combines Astromech's Large Life Model with Form Bio's FormSightAI and manufacturing platforms to improve therapeutic development.

What happened

Astromech announced on November 17, 2026, that it had acquired Form Bio in an all-stock deal valued at $230 million. The acquisition brings together Astromech's evolutionary AI technology with Form Bio's tools for designing and manufacturing genetic medicines. Form Bio's team and intellectual property will join Astromech, with Form Bio co-founder Andrew Busey taking on a leadership role overseeing AI and technology. The companies plan to integrate their platforms to improve gene therapy vector design and genomic quality assessment.

Key details

  • Acquisition price was $230 million, paid in stock.
  • Form Bio's FormSightAI and manufacturing tools will be combined with Astromech's Large Life Model, which is still in development.
  • Andrew Busey, Form Bio's co-founder, is now Astromech's Chief AI Officer and Head of Technology.
  • Form Bio previously reported increasing full-genome content in gene therapy vectors from 13% to 59% in one month for a Duchenne muscular dystrophy candidate.

Why it matters

Researchers and companies developing genetic medicines will have access to a combined platform that aims to improve the design and manufacturing quality of gene therapy vectors. This could reduce unwanted components earlier in development, potentially lowering the need for downstream purification and speeding up progress toward regulatory approval. Organizations using Form Bio's tools may see expanded capabilities as Astromech's evolutionary AI is integrated into the design process.


More in Healthcare